Teva Pharmaceutical has announced a significant milestone in its biosimilar portfolio with the U.S. Food and Drug Administration (FDA) granting…
Read More
The UK Must Supercharge Its Commercial Strategy to Boost Global Life Sciences Competitiveness
Off the northwestern coast of mainland Europe, an island nation with significant ambitions for its life sciences sector is navigating…
Read More
Groundbreaking Diagnostic Innovations Promise to Halve Endometriosis Diagnosis Delays, Yet Systemic Hurdles Persist
Endometriosis, a debilitating chronic inflammatory condition affecting an estimated 10% of reproductive-age women globally, continues to be plagued by a…
Read More
The Rise of Antibody-Drug Conjugates: Precision Oncology’s Evolving Frontier
Antibody-drug conjugates (ADCs) represent a significant leap forward in targeted cancer therapy, a sophisticated class of drugs that marries the…
Read More
Otsuka Pharmaceutical to Acquire Transcend Therapeutics for Up to $1.225 Billion to Bolster Psychiatric and Neurological Pipeline
TOKYO, JAPAN & BOSTON, USA – March 30, 2026 – Otsuka Pharmaceutical Co., Ltd. announced today that its subsidiary, Otsuka…
Read More
MSD’s $6.7 Billion Acquisition of Terns Pharmaceuticals Signals a Bold Strategic Pivot in Oncology to Secure Future Growth
On March 25, Merck & Co. (MSD) announced a significant strategic move, acquiring Terns Pharmaceuticals for an estimated $6.7 billion…
Read More
The Crucial Role of Payload Linker Innovation in the Rapidly Expanding Antibody-Drug Conjugate Market
Combining the targeted precision of monoclonal antibodies with the potent destructive power of cytotoxic payloads, Antibody-Drug Conjugates (ADCs) represent a…
Read More
Novo Nordisk Secures FDA Approval for Awiqli, a Once-Weekly Basal Insulin for Adults with Type 2 Diabetes
The United States Food and Drug Administration (FDA) has granted approval to Novo Nordisk for Awiqli (insulin icodec-abae) injection 700…
Read More
Simulations Plus Forges Strategic Alliances to Pioneer AI-Driven Drug Development
Simulations Plus, a leading provider of advanced modeling and simulation software for drug discovery and development, has announced the establishment…
Read More
Novartis to Acquire Excellergy for Up to $2 Billion to Bolster Next-Generation Anti-IgE Allergy Pipeline
Novartis has entered into a definitive agreement to acquire Excellergy, a privately held biotechnology company specializing in the development of…
Read More
